Baird-Sponsored Microwave Ablation Training Advances Thyroid Treatment
Rhea-AI Summary
Baird Medical (NASDAQ: BDMD) recently sponsored an advanced Microwave Ablation (MWA) training session in New Orleans, focusing on thyroid nodule treatment. The program was led by Dr. Emad Kandil from Tulane University School of Medicine, with participation from Dr. Sean P. Nikravan and Dr. Erin H. Lin.
Participants observed seven live MWA procedures, gaining hands-on experience in precision targeting and workflow optimization. The training emphasized the technology's efficiency and potential for improved patient outcomes, including faster recovery times. Following the session, the physicians engaged in clinical discussions and received Certificates of Completion.
Chairwoman Haimei Wu emphasized the importance of hands-on training and expert collaboration in advancing MWA technology adoption for thyroid treatments.
Positive
- Successfully conducted training program demonstrating MWA technology to potential adopters
- Engagement of prominent medical professionals from major institutions
- Practical demonstration of technology through 7 live procedures
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, BDMD gained 25.40%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Led by Dr. Emad Kandil, Professor and Ellis Hanna Chair in Surgery at Tulane University School of Medicine, the session welcomed participation from Dr. Sean P. Nikravan, MD, FACE, an endocrinologist based in
Following the session, Dr. Nikravan and Dr. Lin participated in post-training discussions with Dr. Kandil, exchanging valuable clinical insights and strategies for adopting MWA in diverse clinical settings. Upon completing the program, both physicians were awarded Certificates of Completion, signifying their readiness to incorporate this advanced treatment modality into their practice.
"Advancing the development of MWA for thyroid nodules requires hands-on training and expert collaboration," said Haimei Wu, Chairwoman of Baird Medical. "By supporting specialized programs like this, we are empowering physicians with the practical expertise needed to refine patient care and drive broader adoption of minimally invasive thyroid treatments."
About Baird Medical
Baird Medical is a leading provider of minimally invasive microwave ablation (MWA) technology, offering advanced treatment solutions for conditions such as thyroid nodules, breast disease, uterine fibroids, and liver cancer. A publicly traded company on NASDAQ, Baird Medical is dedicated to enhancing patient care through precision, efficiency, and safety in its innovative medical devices. For more information, please visit https://bairdmed.com/
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts and generally relate to future events or Baird Medical's future financial or operational performance. In some cases, you can identify forward-looking statements by terminology such as "may," "might," "will," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue," or the negative of these terms or other similar expressions.
These forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual results or outcomes to differ materially from those expressed or implied. These statements are based on estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. Risks and uncertainties may emerge over time, and it is not possible to anticipate all potential factors that could affect Baird Medical's business and financial performance.
Factors that could cause actual results to differ materially include, but are not limited to: (1) the risk that Baird Medical may not achieve its expansion goals in
Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Baird Medical undertakes no obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.
View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-sponsored-microwave-ablation-training-advances-thyroid-treatment-302348718.html
SOURCE BDMD